Innovating.works Conecta tu I+D

SAPHIRE: Securing Adoption of Personalised Health in REgions BELFAST HEALTH AND SOCIAL CARE TRUST participó en un H2020 H2020-SC1-BHC-2018-2020 SAPHIRE or the consortium for Securing Adoption of Personalised Health in REgions: The consortium eSAPHIRE or the consortium for Securing...
2018-11-14 - 2022-05-31 | financed

SPARK: Supporting Pioneer doctoral Researchers through 3i Knowledge partnerships BELFAST HEALTH AND SOCIAL CARE TRUST participó en un H2020 H2020-MSCA-COFUND-2016 The SPaRK Programme is driven by the need to develop future leaders whose skills combine disciplinary excellence with a capacity for interdi...
2017-04-03 - 2022-04-30 | financed

TO-REACH: Transfer of Organisational innovations for Resilient Effective equitable Accessible sustainable... BELFAST HEALTH AND SOCIAL CARE TRUST participó en un H2020 H2020-SC1-2016-2017 In order to strengthen the sustainability and resilience of health services and systems a unique consortium of governmental and funding orga...
2016-11-30 - 2021-05-31 | financed

MIDAS: Meaningful Integration of Data Analytics and Services BELFAST HEALTH AND SOCIAL CARE TRUST participó en un H2020 H2020-SC1-2016-2017 The MIDAS consortium is a partnership involving health authorities in five EU countries and the U.S. and technical big data experts from res...
2016-10-12 - 2020-02-29 | financed

MAGIC: Mobile Assistance for Groups Individuals within the Community STROKE REHABILITATION MAGIC Post Stroke Project Team has united members from across Europe, dedicated to enable significant change in the delivery of health & soc...
2015-12-01 - 2020-10-31 | financed

CHESS: Connected Health Early Stage Researcher Support System BELFAST HEALTH AND SOCIAL CARE TRUST participó en un H2020 H2020-MSCA-ITN-2015 Changing demographics and increasing pressure on health related resources mean that new models of care must be found. Fortunately, technolo...
2015-07-29 - 2019-08-31 | financed

NEPHSTROM: Novel Stromal Cell Therapy for Diabetic Kidney Disease BELFAST HEALTH AND SOCIAL CARE TRUST participó en un H2020 H2020-PHC-2014-2015 Type 2 diabetes will affect >500 million adults by 2040 and its secondary complications will generate enormous socioeconomic costs - in part...
2015-04-08 - 2021-10-31 | financed

Remediate: Improved decision making in contaminated land site investigation and risk assessment BELFAST HEALTH AND SOCIAL CARE TRUST participó en un H2020 H2020-MSCA-ITN-2014 The REMEDIATE ETN comprises 10 beneficiaries (from 5 EU Member States – the UK, Ireland, Germany, Denmark, and Italy) and 15 partner organis...
2014-12-12 - 2018-12-31 | financed

WASTCArD: Wrist and arm sensing technologies for cardiac arrhythmias detection BELFAST HEALTH AND SOCIAL CARE TRUST participó en un H2020 H2020-MSCA-RISE-2014 Abnormal heart rhythms are a major cause of cardiovascular disease and death in Europe. Sudden cardiac death accounts for 50% of cardiac mo...
2014-12-02 - 2018-04-30 | financed

IABC PROGRAMME: iABC Programme BELFAST HEALTH AND SOCIAL CARE TRUST participó en un FP6 Cystic Fibrosis (CF) is a common fatal inherited disease with a frequency of 1 in 2500 live births, affecting approximately 36,000 (0.737/10...
2015-08-01 - 2021-12-31 | financed

MERCURIC: A Phase Ia b study of MEK1 2 inhibitor PD 0325901 or MEK 162 with cMET inhibitor PF 02341066 in RASM... BELFAST HEALTH AND SOCIAL CARE TRUST participó en un FP7 Colorectal cancer (CRC) is the 3rd most common cancer in Europe, and with approximately 200,000 deaths per year, it remains the 2nd most com...
financed

EPIPGX: Epilepsy Pharmacogenomics delivering biomarkers for clinical use BELFAST HEALTH AND SOCIAL CARE TRUST participó en un FP7 The purpose of the project is to identify genome-based biomarkers for use in clinical practice to individualise treatment of epilepsy, and s...
financed

NEUROSIS: Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dyspl... BELFAST HEALTH AND SOCIAL CARE TRUST participó en un FP7 HYPOTHESIS: Early inhalation of Budesonide (BS) reduces the absolute risk of developing bronchopulmonary dysplasia (BPD) or death in preterm...
financed

IABC PROGRAMME: iABC Programme BELFAST HEALTH AND SOCIAL CARE TRUST participó en un FP7 Cystic Fibrosis (CF) is a common fatal inherited disease with a frequency of 1 in 2500 live births, affecting approximately 36,000 (0.737/10...
financed

EUROCOURSE: Europe against Cancer Optimisation of the Use of Registries for Scientific Excellence in research EUROCOURSE will tackle fragmentation in the funding and usage of cancer registries in Europe. It will do so by exploring ways to link and in...
financed

S-HELP: Securing Health.Emergency.Learning.Planning BELFAST HEALTH AND SOCIAL CARE TRUST participó en un FP7 Volatile events such as disasters bring the prospect of rapid contagion and the threat of disastrous impacts for Europe. Vulnerabilities and...
financed

ENCE-CF-LAM-LTX: European Networks of Centres of Expertise for CF Cystic Fibrosis LAM Lymphangioleiomyomatosis... BELFAST HEALTH AND SOCIAL CARE TRUST participó en un FP7 European Centres of Expertise Networks for rare diseases have been identified by the European Commission as one important area of future act...
financed

DISCHARGE: Diagnostic Imaging Strategies for Patients with Stable Chest Pain and Intermediate Risk of Coronary... BELFAST HEALTH AND SOCIAL CARE TRUST participó en un FP7 Coronary artery disease (CAD) is the leading cause of death in high-income countries. Invasive coronary angiography (ICA) is the reference s...
financed

CLEANWARD: Safe Chemical Free Cleaning of Hospital Ward Surfaces BELFAST HEALTH AND SOCIAL CARE TRUST participó en un FP7 Cleanward aims to develop a novel, safe, user-friendly anti-microbial cleaning system, using titanium dioxide coated ultra-microfibre fabric...
financed

BHSCT